Search
Results
showing 1-10 of 2297
Global Health Watch: NIH reopens South Africa Research Funding; DRC Ebola Strains Outbreak Response; WHO + FDA Leadership Shifts
August 2026
The US National Institutes of Health (NIH) lifted research funding restrictions on South Africa; the DRC’s Ebola outbreak grows, exposing the consequences of weakened outbreak-response systems; and leadership changes at the World Health Organization (WHO) and the US Food and Drug Administration (FDA) raise questions about the future of global health decision-making.
The Latest Resources from AVAC: Advancing Science, Expanding Access
August 2026
Scientific breakthroughs accelerate HIV prevention—but only when they are matched with bold advocacy, sustained investment and equitable access. This month’s roundup highlights key prevention news, developments and takeaways from AVAC and explores what’s needed and what’s next to ensure the latest innovations move beyond headlines and into the hands of the communities that need them most.
EXPrESSIVE Phase III Program Countries of Alimatravir
August 2026
Seventeen countries are hosting sites for the Phase III efficacy trials of a monthly PrEP pill, called MK-8527, now known as alimatravir, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase III trials at IAS 2025 in Kigali. Alimatravir (AMI) was found to be safe and well-tolerated in Phase II clinical trials.
Years Ahead in HIV Prevention Research: Time to Market
August 2026
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
HIV Prevention Pipeline: Products to Watch
August 2026
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
People’s Research Agenda 2025 Update Summary Table
August 2026
The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.
Alimatravir (AMI) Licensing Timeline
August 2026
This timeline demonstrates the speed of generic licensing for alimatravir (AMI) compared to lenacapavir (LEN) and cabotegravir (CAB).
ARV-Based and Multipurpose Prevention Technology R&D Pipeline
August 2026
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
The HIV Prevention Pipeline
August 2026
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.
An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible
August 2026
The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.
showing 1-10 of 2297